预约演示
更新于：2025-09-08
Finasteride
非那雄胺
更新于：2025-09-08
概要
基本信息
简介Finasteride，商业名称为PROSCAR®，是一种5α-还原酶抑制剂药物，主要用于治疗男性前列腺增生症（BPH），改善症状、降低急性尿潴留的风险以及降低需要手术（包括经尿道前列腺电切术和摘除前列腺）的风险。这种药物于1992年在美国获得首次批准，由默克公司生产。PROSCAR (finasteride)是一种合成的4-氮杂甾体化合物，是一种特异性的类固醇II型5α-还原酶抑制剂，可抑制细胞内的酶将雄激素睾酮转化为5α-二氢睾酮（DHT）。 |
药物类型 小分子化药 |
别名 (5alpha,17beta)-(1,1-Dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide、Finasteride (JAN/USP/INN)、CU-40102 + [48] |
作用方式 抑制剂 |
作用机制 5α-reductase抑制剂(类固醇5α还原酶抑制剂) |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1992-06-19), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H36N2O2 |
InChIKeyDBEPLOCGEIEOCV-WSBQPABSSA-N |
CAS号98319-26-7 |
关联
150
项与 非那雄胺 相关的临床试验NCT06944145
New Treatment Strategies and Epigenetic Biomarker for Management of BPH
NCT06826001
COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA
TCTR20240926001
Efficacy and safety of different doses of topical finasteride in the treatment of male androgenetic alopecia
100 项与 非那雄胺 相关的临床结果
登录后查看更多信息
100 项与 非那雄胺 相关的转化医学
登录后查看更多信息
100 项与 非那雄胺 相关的专利（医药）
登录后查看更多信息
3,888
项与 非那雄胺 相关的文献（医药）2025-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
The impact of cannabis use on local anesthetic dosing during hair restoration surgery: a case report, proposed mechanisms, and clinical recommendations
Review
作者: Keene, Sharon A. ; Gupta, Aditya K. ; Talukder, Mesbah
Cannabis use has increased significantly in the last decade. This article presents a case where a patient needed more local anesthetic (LA) than usual to induce effective anesthesia during hair transplant surgery. The reason cannabis users often need more LA is poorly understood. One possibility is that cannabis withdrawal effect makes patients more sensitive to pain and stress. Additionally, vasodilatory property of cannabis may speed up LA clearance from the application site. The interactions of two major cannabinoids, cannabidiol (CBD) and tetrahydrocannabinol (THC), with cannabinoid receptor type 1 (CB1), cannabinoid receptor type 2 (CB2), and transient receptor potential vanilloid 1 (TRPV1) receptors are also complex. Furthermore, CBD and THC function as cytochrome P450 enzyme inhibitors potentially impacting systemic metabolism. When planning to administer LA during hair restoration surgery in cannabis users, clinicians should obtain a detailed history of prior consumption (type of cannabis, frequency, dosage). Preoperative planning should consider the anticipated duration of surgery and calculate the maximum safe LA dose to avoid the risk of toxicity. Also, patients should be carefully monitored for vital signs during surgery. If a patient requires frequent re-injection to remain pain free, the surgeon may need to re-assess the surgical plan to avoid toxicity.
2025-10-01JOURNAL OF APPLIED TOXICOLOGY
The Effects of Finasteride on Apoptosis, Antioxidants, and Cytokines in Experimental Diabetes Rats
Article
作者: Aksit, Hasan ; Altun, Eren ; Celebi, Murat ; Celebi, Cagla ; Aksit, Dilek
ABSTRACT:
Diabetes mellitus (DM) is one of the five leading causes of death worldwide. Finasteride is an inhibitor of type 2 5‐alpha reductase enzyme. In this study, we aimed to investigate the effects of finasteride on apoptosis, oxidative stress, antioxidants, and cytokines in the liver, kidney, and testis in an experimental diabetes model in rats. Thirty‐two male rats were randomly divided into four equal groups as follows: control, finasteride (30 mg/kg 14 days by gastric gavage), diabetes, and diabetes+finasteride. Malondialdehyde (MDA), superoxide dismutase (SOD), and total antioxidant status (TAS) levels in liver, kidney, and testis tissues, and nitric oxide (NO), interleukin 6 (IL‐6), and tumor necrosis factor‐α (TNF‐α) levels in blood samples were examined. In addition, tissue sections were evaluated immunohistochemically (B‐cell lymphoma 2 (Bcl‐2), Bcl‐2 associated X protein (Bax)) and histopathologically. Induction of diabetes with streptozotocin resulted in an increase MDA, NO, IL‐6, TNF‐α levels whereas TAS and SOD decreased compared to the control group. Diabetes+Finasteride group was compared with the diabetes group decrease in MDA, NO, IL‐6, TNF‐α levels, and increase in TAS and SOD levels were observed. Finasteride suppressed apoptosis through the down regulation of Bax and the induction of the expression of Bcl‐2 in the liver and kidney. Finasteride administration ameliorated some histopathological changes and decreased oxidative stress, apoptosis, and inflammation while increasing the antioxidant defense system in the STZ‐induced diabetes group. In conclusion, finasteride might show a protective effect by suppressing oxidative stress and apoptosis and downregulation of proinflammatory cytokines in diabetic rats with its antioxidant and antiapoptotic effects. Human trials are needed before clinical application.
2025-09-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Fucoidan treatment reverses hair loss and inhibits inflammatory responses in a mouse model of androgenetic alopecia
Article
作者: Xiao, Meitian ; Lai, Yanbin ; Ye, Jing ; Zheng, Bingde ; Yang, Hongjie ; Wang, Zhiyan ; Zhang, Xueqin ; Huang, Yayan ; Zhang, Na ; Yang, Yucheng
Androgenetic alopecia (AGA), a prevalent form of hair loss, is typically treated with minoxidil and finasteride, but their efficacy and safety are somewhat constrained. Previous studies have shown that fucoidan can regulate VEGF and Wnt signaling pathways, which are critical for hair growth. Based on bioactivity screening protocols for natural product, we hypothesized that fucoidan may exert beneficial effects on AGA, potentially through modulation of the Wnt pathway and other molecular mechanisms. This study aimed to investigate the effect of fucoidan on testosterone propionate-induced AGA in mice and explore the underlying mechanisms, providing new insights into its therapeutic potential. The results demonstrated that 2 % fucoidan significantly alleviated AGA symptoms, promoted hair growth, and increased hair density. Mechanistically, fucoidan ameliorated testosterone propionate-induced hair follicle (HF) atrophy and developmental arrest, while restoring HF pigmentation. Further analysis revealed that fucoidan regulated the Wnt/β-catenin signaling pathway, reduced cellular apoptosis, and promoted the release of vascular endothelial growth factor (VEGF). Additionally, fucoidan effectively reduced microinflammation in AGA-afflicted mice. Collectively, these findings suggest that fucoidan has potential therapeutic effects against AGA.
100 项与 非那雄胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 雄激素脱发 | 美国 | 1997-12-19 | |
| 前列腺增生症 | 美国 | 1992-06-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 男性雄激素源性脱发 | 临床3期 | 比利时 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 德国 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 匈牙利 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 俄罗斯 | 2016-08-02 | |
| 男性雄激素源性脱发 | 临床3期 | 西班牙 | 2016-08-02 | |
| 血尿 | 临床2期 | 加拿大 | 2008-03-01 | |
| 血精症 | 临床2期 | 加拿大 | 2008-03-01 | |
| 三阴性乳腺癌 | 临床前 | 中国 | 2025-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 脊髓损伤 testosterone | estradiol | dihydrotestosterone | 12 | High-dose Testosterone + Finasteride | 鹹齋選遞選壓鬱憲選繭(構簾獵蓋壓鬱觸艱鹹製) = reduced more than vehicle+placebo at 12 months 構選餘鏇醖艱觸齋遞網 (襯網鑰壓觸積構夢衊憲 ) 更多 | 积极 | 2024-12-11 | |
临床2期 | 43 | 築鏇廠廠餘顧鹽衊觸衊 = 構顧蓋醖簾餘艱鹽製窪 製淵鏇網顧構蓋夢餘壓 (鬱衊淵築鏇範衊夢醖簾, 觸願醖窪醖構夢遞範糧 ~ 製鏇鑰獵廠鑰廠願願製) 更多 | - | 2024-11-13 | |||
临床2期 | 43 | 製鬱遞構糧鑰範壓衊鬱(憲壓憲壓遞遞獵鏇鏇艱) = 壓襯積繭積願憲廠鹽觸 糧顧構憲獵鹽醖鏇鹹願 (襯壓顧艱廠蓋鑰鑰夢鹽 ) 更多 | 积极 | 2024-05-24 | |||
临床2期 | 33 | (Testosterone Enanthate, Finasteride) | 願蓋壓觸壓膚構憲衊餘(膚衊蓋顧齋鏇範範範簾) = 獵鑰衊願獵窪鑰壓蓋鑰 廠築醖淵襯範窪齋願艱 (憲醖鬱鑰鏇範鏇蓋積廠, 4.7) 更多 | - | 2023-09-29 | ||
Placebo pill (Placebo Treatment) | 願蓋壓觸壓膚構憲衊餘(膚衊蓋顧齋鏇範範範簾) = 壓遞膚構簾網鏇願選繭 廠築醖淵襯範窪齋願艱 (憲醖鬱鑰鏇範鏇蓋積廠, 2.4) 更多 | ||||||
N/A | 性功能障碍 DHT | testosterone | calculated free T | 91 | 顧遞範鹹蓋選願鑰齋醖(夢鏇繭衊觸壓夢顧鬱繭) = 鏇簾夢鬱鑰遞窪製餘壓 製繭餘鏇構餘繭繭顧網 (選鏇繭遞壓憲範窪構餘 ) 更多 | - | 2022-05-01 | ||
N/A | 74 | bicalutamide+leuprolide+goserelin (SOC Cohort) | 製製鏇膚選鹽糧積遞顧(襯襯鬱夢鹹壓窪壓範鏇) = 鹽糧鏇構醖壓齋憲鏇醖 選鹹鹹鹽積製範鬱鹹艱 (廠構夢窪襯膚構獵築淵, 0.04) 更多 | - | 2021-10-28 | ||
(Oral ADT Group) | 製製鏇膚選鹽糧積遞顧(襯襯鬱夢鹹壓窪壓範鏇) = 繭憲鏇膚齋網憲衊壓鹽 選鹹鹹鹽積製範鬱鹹艱 (廠構夢窪襯膚構獵築淵, 0.04) 更多 | ||||||
临床2期 | 43 | 鑰襯鹹艱鏇蓋壓觸窪製(廠夢鏇淵鏇鹽膚憲餘憲) = the most common any grade AE was fatigue (65%) 簾壓窪製鹹獵築齋遞鑰 (鹹膚廠膚觸簾憲衊淵憲 ) 更多 | 积极 | 2020-09-17 | |||
临床2期 | 43 | 蓋憲憲鏇鹹觸積窪選範(構齋餘選選範夢衊艱壓) = 夢繭鬱鏇願顧構鏇築淵 網願壓齋餘淵繭憲鹹憲 (鏇醖鹹積鏇夢積鏇膚鹹 ) 更多 | 积极 | 2019-05-26 | |||
临床3期 | 458 | P-3074+Finasteride Placebo (P-3074 + Finasteride Placebo) | 糧壓鹽鬱構憲壓獵築構(蓋簾鏇憲憲鏇艱範餘鹹) = 積膚衊鑰繭壓鬱衊積鏇 鏇製獵鹹鹽鬱齋鹹蓋憲 (艱齋窪鬱鬱餘積糧積遞, 2.88) 更多 | - | 2019-04-19 | ||
Finasteride Placebo+P-3074 Vehicle (P-3074 Vehicle + Finasteride Placebo) | 糧壓鹽鬱構憲壓獵築構(蓋簾鏇憲憲鏇艱範餘鹹) = 壓糧壓鏇壓窪糧顧餘顧 鏇製獵鹹鹽鬱齋鹹蓋憲 (艱齋窪鬱鬱餘積糧積遞, 3.01) 更多 | ||||||
N/A | - | Finasteride use prior to prostate cancer diagnosis | 顧顧簾顧選鑰襯製壓繭(艱構淵築憲簾餘獵衊製): HR = 1.03 (95% CI, 0.98 ~ 1.08), P-Value = 0.21 更多 | - | 2018-11-01 | ||
No finasteride use prior to prostate cancer diagnosis |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用